Cancer cells rely on dysregulated gene expression. This establishes specific transcriptional addictions that may be therapeutically exploited. Yet, the mechanisms that are ultimately responsible for these addictions are poorly understood. Here, we investigated the transcriptional dependencies of transformed cells to the transcription factors YAP and TAZ. YAP/TAZ physically engage the general coactivator bromodomain-containing protein 4 (BRD4), dictating the genome-wide association of BRD4 to chromatin. YAP/TAZ flag a large set of enhancers with super-enhancer-like functional properties. YAP/TAZ-bound enhancers mediate the recruitment of BRD4 and RNA polymerase II at YAP/TAZ-regulated promoters, boosting the expression of a host of growth-regulating genes. Treatment with small-molecule inhibitors of BRD4 blunts YAP/TAZ pro-tumorigenic activity in several cell or tissue contexts, causes the regression of pre-established, YAP/TAZ-addicted neoplastic lesions and reverts drug resistance. This work sheds light on essential mediators, mechanisms and genome-wide regulatory elements that are responsible for transcriptional addiction in cancer and lays the groundwork for a rational use of BET inhibitors according to YAP/TAZ biology. c 10 µm 180 Input G S T G S T -Y A P d e f g h i j Fig. 1 | BRD4 associates to YAP/TAZ and is a required cofactor for YAP/TAZ transcriptional activity. a, Interaction of endogenous YAP/TAZ, TEAD1 and BRD4 in MDA-MB-231 cells. Each co-IP experiment was performed three times with similar results. b, Endogenous YAP, TAZ or TEAD1 and exogenous FLAG-BRD4 or HA-BRD4 interact in the nuclei of HEK293T cells, as shown by the PLA signal (red fluorescent dots). Nuclei are counterstained with DAPI (blue). No red dots could be detected in the nuclei of cells transfected with empty vector, confirming the specificity of interactions. Similar results were obtained in two additional experiments. c, Recombinant BRD4 (rBRD4) is pulled down by the GST-YAP fusion protein. GST pulldown was repeated three times with similar results. WB, western blot. d, Genes activated by YAP/TAZ (n = 2,073) display higher expression levels than genes that are not activated by YAP/TAZ (not YAP/TAZ (YT) targets, n = 8,026) in MDA-MB-231 cells. The expression values (in RPKM) were determined by RNA-seq and are presented as box-and-whiskers plots (whiskers extend from the 10th to the 90th percentile; the box extends from the 25th to the 75th percentile; the line within the box represents the median). ****P < 10 -10 (one-tailed Mann-Whitney U -test). See also Supplementary Fig. 1g . e, Box-and-whiskers plots of the expression values of genes involved in cell proliferation (n = 1,449) versus genes that are associated with all other functions (n = 8,650) according to the GO annotation. Data are presented as in d. ****P < 10 -10 (one-tailed Mann-Whitney U-test); ++++ P < 10 -10 (one-tailed Wilcoxon matched-pairs signed rank test). f, The fraction of genes activated by YAP/TAZ that are inhibited by JQ1 or BRD2/3/4 siRNAs is larger than the fraction of all expressed genes downregulated by the same treatments. See also Supplementary Fig. 1i . g, Fold change in gene expression of not YAP/TAZ targets (n = 8,026) versus genes that are activated by YAP/TAZ (n = 2,073) upon treatment with JQ1 or BET protein depletion. The y axis shows the fold change in the transcript levels versus DMSO-treated cells or cells transfected with siCO. Data are presented as box-and-whiskers plots, as in d. ****P < 10 -10 (one-tailed Mann-Whitney U-test). h, Fold change in gene expression of high-confidence YAP/TAZ direct targets (n = 616) versus not YAP/TAZ targets (n = 771) upon treatment with JQ1 or BET protein depletion. The group of not YAP/TAZ targets represents genes that are not significantly affected by YAP/TAZ depletion (FDR > 0.05) in our RNA-seq data set. Data are presented as box-and-whiskers plots, as in d. ****P < 10 -10 (one-tailed Mann-Whitney U-test). i, The expression level of all YAP/TAZ-activated genes (n = 2,073) in MDA-MB-231 cells treated with DMSO (vehicle), BET inhibitors (JQ1 or OTX015), CDK inhibitors (flavopiridol or THZ1) or RG-108 (a DNA methyltransferase inhibitor, here used as a negative control to assess the effect of a compound targeting an epigenetic function that is not related to YAP/TAZ-dependent transcription). The expression levels were determined by RNA-seq and are presented as z-scores. Individual genes and their mean (black line) are presented. x axis is represented as a black dotted line. j, Odds ratio plot. The genes activated by YAP/ TAZ (n = 2,073) are more likely to be inhibited by BET inhibitors than the not YAP/TAZ target genes. The CDK inhibitors and RG-108 do not display such properties (see Methods). The red dashed line is odds ratio = 1 (i.e., no association between regulation by YAP/TAZ and response to drugs).
A n emerging paradigm in cancer biology relates to the concept of 'transcriptional addiction': it posits that, to support their uncontrolled proliferation or other needs, tumor cells set high demands on transcriptional regulators, including chromatin regulators and even the basal transcriptional machinery 1, 2 . The molecular mechanisms underlying the transcriptional dependency of cancer cells are poorly understood. Yet, it is an appealing concept, as general chromatin regulators or transcriptional cofactors are amenable to inhibition with small molecules 2 . The emblematic example is the antitumor activity of bromodomain and extraterminal domain (BET) inhibitors in various xenograft model systems and clinical trials [3] [4] [5] [6] . BET inhibitors oppose the activity of BET coactivators (that is, bromodomain-containing protein 4 (BRD4) and its related factors BRD2 and BRD3) 5 . Although BET proteins have been proposed to serve as general regulators of RNA polymerase II (Pol II)-dependent transcription, genome-wide studies have instead shown that BET inhibitors display selective effects on gene expression 5, 7 . In particular, BET inhibitors have been reported to have a disproportional effect on a set of highly expressed genes associated with super-enhancers 5, 7 . The molecular basis of the transcriptional addiction associated to super-enhancers in cancer cells, as well as the determinants of the selectivity of BET inhibitors remain undefined 8 .
The transcriptional coactivators YAP (Yes-associated protein)/ TAZ (transcriptional coactivator with PDZ-binding motif) are ideal candidates to mediate cancer-specific transcriptional addictions. In fact, YAP/TAZ are genetically dispensable for homeostasis in many adult tissues [9] [10] [11] [12] [13] [14] [15] [16] [17] , whereas YAP/TAZ activation is a hallmark of many human malignancies 13, [17] [18] [19] . Here, we show that tumor transcriptional dependencies in fact overlap with tumor reliance on YAP/TAZ.
Results
BRD4 interacts with YAP/TAZ. With this background in mind, we started this investigation by carrying out chromatin immunoprecipitation with mass spectrometry (ChIP-MS) for endogenous YAP/TAZ, a procedure that allows the study of the composition of the native protein complexes entertained by YAP/TAZ and, in particular, nuclear interactions 20 . We detected some well-known nuclear partners of YAP/TAZ, including TEAD (the main YAP/ TAZ DNA-interacting partner) and activator protein 1 (AP-1) family members 13 and several subunits of the SWI/SNF complex 21 . YAP/ TAZ protein complexes were also enriched in chromatin readers or modifiers, such as BRD4, histone acetyltransferases (HATs; p300 and p400) and the histone methyltransferase KMT2D (also known as MLL2) (Supplementary Table 1 ). The roles of p300, SWI/SNF and the H3K4 methyltransferase complexes in the context of YAPdependent transcription have been previously described [21] [22] [23] . The association with BRD4 attracted our attention, as this hinted to a connection between YAP/TAZ-regulated gene expression and the transcriptional addiction of cancer cells.
To validate the interactions detected by ChIP-MS, we performed co-immunoprecipitation (co-IP) of endogenous proteins, revealing the presence of BRD4 and TEAD1 in YAP and TAZ immunocomplexes, and of YAP, TAZ and TEAD1 in BRD4 immunocomplexes (Fig. 1a ). By proximity ligation assays (PLAs), we validated that this interaction occurs in the nucleus (Fig. 1b ). Furthermore, by co-IP, transfected FLAG-tagged YAP co-purified endogenous BRD4 and BRD2 ( Supplementary Fig. 1a ). Importantly, the association between YAP or TAZ and BRD4 is direct, as attested by the interactions between purified recombinant proteins ( Fig. 1c and Supplementary Fig. 1b ). By using progressive carboxy-terminal deletion constructs, we mapped the minimal region sufficient for association with BRD4 between amino acids 108 and 175 of mouse TAZ ( Supplementary Fig. 1b,c) ; notably, this region includes the WW domain 24 . However, removal of the sole WW domain from full-length TAZ did not impair its ability to associate with BRD4 ( Supplementary Fig. 1d ), indicating that another determinant for BRD4 association exists in the C-terminal transactivation domain. Overall, the data indicate that YAP, TAZ, TEAD1 and BET proteins are part of the same nuclear multiprotein complex.
YAP/TAZ mediate cancer transcriptional addiction.
To study the connection between YAP/TAZ and transcriptional addiction in cancer, we used MDA-MB-231 cells, a well-established model of triple-negative breast cancer (TNBC), a tumor type that requires high levels of uninterrupted transcription of a large set of genes to sustain its particularly aggressive nature 25, 26 . Are YAP/TAZ causal to these dependencies? By comparing the transcriptional profiles (obtained by RNA sequencing (RNA-seq)) of control and YAP/TAZ-depleted cells ( Supplementary Fig. 1e ,f), we found that genes whose expression depends on YAP/TAZ were significantly more expressed than all the other genes ( Fig. 1d ); this conclusion was confirmed also when we restricted our analyses to high-confidence direct YAP/ TAZ target genes, that is, genes dependent on YAP/TAZ whose promoters or enhancers contain YAP/TAZ-binding sites as assessed by ChIP followed by sequencing (ChIP-seq) 13 ( Supplementary Fig. 1g ). Moreover, genes whose biological function is associated with cell proliferation (~1,500 genes, as determined by Gene Ontology (GO) annotation) were transcribed at higher levels than the bulk of expressed genes (Fig. 1e ); silencing YAP/TAZ with siRNAs led to a global downregulation of such a 'growth program' (Fig. 1e ), in line with the previous report that MDA-MB-231 cells depleted of YAP/TAZ undergo growth arrest 13 . Indeed, 37% of the growth genes actively transcribed in these cells are YAP/TAZ targets (541 out of 1,449); their transcripts were particularly abundant, displaying a higher level of expression than non-YAP/TAZ targets associated with the same biological function ( Supplementary Fig. 1h ). Thus, the activation of essential growth genes in MDA-MB-231 cells relies on YAP/TAZ.
Vulnerability of YAP/TAZ activity to BET inhibitors.
To assess whether the interaction with BRD4 is causal for the activation of YAP/ TAZ transcriptional targets, we performed RNA-seq in cells treated with JQ1, the most established BET inhibitor. JQ1 occupies the bromodomain pockets of BET proteins in a manner that is competitive with the binding to acetylated histone tails, causing their displacement from chromatin 4 . Most YAP/TAZ-regulated genes (68%) displayed exquisite sensitivity to JQ1 ( Fig. 1f and Supplementary Fig. 1i ), and vice versa: genes that were most effectively downregulated by JQ1 were in fact YAP/TAZ dependent ( Supplementary Fig. 1j ). Indeed, treatment with JQ1 selectively decreased the transcript abundance of YAP/TAZ-dependent genes compared to all other active genes (Fig. 1g ). The disproportional effect of JQ1 was confirmed when we restricted our analyses to high-confidence direct YAP/TAZ target genes (Fig. 1h ). The bias of JQ1 towards inhibition of YAP/TAZ-dependent genes (including direct targets) was also evident when restricting the analysis to genes regulating cell proliferation ( Supplementary  Fig. 1k -l): BET inhibition affected the expression of 604 genes associated to GO terms linked to cell proliferation and 428 of these (71%) were regulated by YAP/TAZ. Thus, the sensitivity of a broad number of growth-regulating genes to BET inhibition relies on YAP/TAZ. Effects similar to those of JQ1 were obtained with another BET inhibitor (OTX015; Fig. 1i ,j and Supplementary  Fig. 1l ,o) and by knocking down BRD2/3/4 with two independent combinations of siRNAs ( Fig. 1g,h) . Moreover, the depletion of the sole BRD4 was sufficient, at least in part, to downregulate YAP/TAZ target genes ( Supplementary Fig. 1m ). We also found that endogenous YAP/TAZ remained nuclear upon treatment with BET inhibitors ( Supplementary Fig. 1n ), excluding the possibility that the compounds would indirectly cause YAP/TAZ cytoplasmic relocalization.
YAP/TAZ transcriptional control has been connected to cyclindependant kinase 9 (CDK9)-induced elongation of nascent transcripts by Pol II 27 . Here, we find that, in stark contrast with BET inhibitors, inhibition of transcriptional CDKs with flavopiridol or THZ1 failed to display any bias towards inhibition of YAP/ TAZ transcriptional targets (Fig. 1i,j and Supplementary Fig.  1o ). Collectively, the data indicate that the physical association between YAP/TAZ and BRD4 is functionally relevant; BRD4 is a required cofactor for YAP/TAZ, conferring to YAP/TAZ target genes a specifically high dependency on BRD4 and vulnerability to BET inhibitors.
BRD4 is recruited to chromatin by YAP/TAZ. We next asked what underlies the disproportionate sensitivity of YAP/TAZ targets to BET inhibitors. To gain mechanistic insights into this connection, we performed ChIP-seq experiments to compare BRD4 and YAP/TAZ binding to chromatin. YAP/TAZ bind almost exclusively to enhancers 13, 23, 27 , whereas BRD4 binds to both active enhancers and active promoters ( Supplementary Fig. 2a,b ; see Methods for the definition of enhancers and promoters). We started our analysis from enhancer elements and found that BRD4 coverage was higher on enhancers containing YAP/TAZ-binding sites than on active enhancers not occupied by YAP/TAZ ( Fig. 2a ). We reasoned that differential BRD4 loading might correspond to differential responsiveness to JQ1; to verify this assumption, we performed BRD4 ChIP-seq in cells treated with JQ1. We found that JQ1 induced a preferential loss of BRD4 from YAP/TAZ-occupied enhancers compared to active enhancers without YAP/TAZ-binding sites ( Fig. 2a and Supplementary Fig. 2c ). Thus, the presence of YAP/TAZ peaks defines enhancers enriched of BRD4 and that are highly sensitive to BET inhibitors on the genome-wide scale. Do these elements correspond to super-enhancers? In fact, 80% of super-enhancers in MDA-MB-231 cells do contain YAP/TAZ peaks; yet, the vast majority (85%) of YAP/TAZ-occupied enhancers are by definition typical enhancers ( Supplementary Fig. 2f ,g). However, we observed that genes connected to YAP/TAZ-bound typical enhancers displayed a sensitivity to JQ1 that was strikingly similar to the much more restricted number of genes associated with super-enhancers ( Supplementary Fig. 2h ).
We then assessed whether the presence of YAP/TAZ was required for the engagement of BRD4 to chromatin, by performing BRD4 ChIP-seq in MDA-MB-231 cells depleted of YAP/TAZ. As shown by the average BRD4-binding profile and some representative enhancers in Fig. 2b ,c, BRD4 recruitment to YAP/TAZ-containing enhancers was heavily reduced upon YAP/TAZ depletion, to an extent similar to JQ1 (see also Supplementary Fig. 2c-e ). The determinants that drive the selectivity of BRD4 association to specific chromatin sites are unclear. BRD4 was reported to bind to some acetylated transcription factors through the bromodomain 5 ; however, arguing against this possibility in the case of YAP/TAZ, we found that their biochemical association with BRD4 is not affected by the presence of JQ1 or by mutations in the BRD4 bromodomains ( Supplementary Fig. 2i ). Thus, the comparable impoverishment of BRD4 recruitment to chromatin detected genome wide after YAP/TAZ depletion or JQ1 treatment reflects the need of a dual 
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association of BRD4 to YAP/TAZ and acetylated histones to keep BRD4 anchored to a large set of enhancers and super-enhancers, as such providing selectivity to BRD4 function. We then surmised that the disproportionate sensitivity of YAP/ TAZ targets to inhibition by JQ1 should be ultimately explained at the level of YAP/TAZ-regulated promoters. Focusing on high-confidence direct YAP/TAZ target genes 13 (see Supplementary Table 2 ), we found that: (1) the transcription start site (TSS) of these genes exhibited higher BRD4 occupancy than the TSS of genes not activated by YAP/TAZ ( Fig. 2d ); (2) YAP/TAZ were required for BRD4 accrual on the promoters of their targets while marginally affecting the promoters of non-YAP/TAZ targets ( Fig. 2e -g; see also Fig. 2h ,i for the representative individual gene tracks and Supplementary  Fig. 2j for validation by ChIP followed by quantitative PCR (ChIP-qPCR)); and (3) JQ1 caused the preferential loss of BRD4 from YAP/TAZ-regulated promoters ( Fig. 2e-g) , matching the effects of JQ1 on gene expression. Importantly, as exemplified in Fig. 2h , JQ1 had only minor effects on BRD4 coverage on the promoters of genes that are not activated by YAP/TAZ, where it was in fact insufficient to induce a general downregulation of transcription ( Fig. 1g,h) . Thus, BRD4 levels at promoters closely reflect the dynamic of YAP/ TAZ-mediated engagement of BRD4 at distant enhancers.
Mechanisms of transcriptional addiction. The data presented above indicate a model whereby YAP/TAZ bound to enhancers promote BRD4 overload on their target promoters, establishing higher expression levels of essential genes and, concomitantly, their vulnerability to BET inhibitors. In agreement with this prediction, treatment with BET inhibitors does not alter YAP/TAZ recruitment to chromatin ( Supplementary Fig. 3a ); yet, BET inhibitors block downstream gene expression, even in conditions in which YAP is overexpressed, consistent with YAP/TAZ acting upstream of BRD4 ( Supplementary Fig. 3b ). In line with this, in the absence of YAP/ TAZ, even overexpressed BRD4 could not promote the expression of YAP/TAZ target genes ( Supplementary Fig. 3c ).
Next, we validated the functional interdependency between YAP/ TAZ and BET proteins by overexpressing YAP5SA (a constitutively active version of YAP) in mammary epithelial cells (MCF10A), which normally display low YAP/TAZ activity. By ChIP, exogenous YAP is recruited at its cognate chromatin sites ( Supplementary Fig. 3d ); in turn, this leads to BRD4 recruitment at the same enhancer sites and associated promoters ( Fig. 3a ). BET inhibitors block BRD4 recruitment to these cis-regulatory elements, supporting the requirement of BRD4 binding to histones along with YAP/TAZ. By gene expression, exogenous YAP turns on its targets, but not in cells treated with JQ1 or depleted of BET proteins ( Fig. 3b and Supplementary Fig. 3e ), indicating that BRD4 operates downstream of YAP/TAZ. The same conclusion applies when we experimentally activated endogenous YAP/TAZ through inactivation of the Hippo pathway ( Supplementary Fig. 3f ).
We next investigated the mechanisms by which BRD4 accrual regulates transcription initiated at YAP/TAZ-target promoters. The role of BRD4 for transcriptional activation is best understood in terms of promotion of elongation through the recruitment of P-TEFb 5 . If so, we should expect that, upon YAP/TAZ depletion or JQ1 treatment, Pol II should remain paused, if not accumulate, on the promoters of YAP/TAZ targets. In contrast to our expectations, by ChIP-seq, Pol II loading was selectively decreased on the promoters of YAP/TAZ targets in YAP/TAZ-depleted MDA-MB-231 cells (Fig. 4a,b and Supplementary Fig. 4a-c ). This implies that YAP/TAZ promote the recruitment of Pol II. Indeed, we detected an association between YAP and Pol II in endogenous complexes by co-IP ( Supplementary Fig. 4d ); intriguingly, this interaction was lost after experimental depletion of BRD4, at least suggesting that 
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NATuRE MEDICINE the latter serves as a key element in connecting YAP/TAZ-bound cis-regulatory elements with the transcriptional apparatus assembled on cognate promoters. In line with this, Pol II coverage on the TSSs of YAP/TAZ target genes was on average higher than all other expressed genes ( Fig. 4a ), proportional to BRD4 binding (Fig. 4c ), and selectively reduced by JQ1 treatment (Fig. 4d ). Representative gene tracks showing comparable effects of JQ1 and YAP/TAZ depletion on Pol II loading on the TSSs of YAP/TAZ target genes (but no substantial effects on non-YAP/TAZ targets) are presented in Fig. 4e and Supplementary Fig. 4e . Similar results were obtained after siRNA-mediated depletion of BRD2/3/4, as revealed by ChIP-qPCR at sampled promoters (Fig. 4f ). This suggests that YAP/TAZ recruit Pol II by inducing BRD4 accumulation at the TSS. BRD4 has been recently reported, and we have repeated, to display an intrinsic acetyltransferase activity, leading to acetylation of K122 in the globular domain of H3 (H2K122ac) 28 . Intriguingly, H3K122ac is associated with Pol II loading on promoters and transcriptional activation 29 ; consistently, we discovered that the HAT domain of BRD4 is indeed crucial for the expression of YAP/TAZ target genes, as a HAT-defective BRD4 (Δ HAT) cannot substitute wild-type BRD4 ( Supplementary Fig. 4f ). We measured the levels of H3K122ac by ChIP-seq in control, YAP/TAZ-depleted or JQ1treated cells. Strikingly, H3K122ac levels were significantly higher on the promoters of YAP/TAZ target genes ( Fig. 4g ), in line with the higher coverage of BRD4 ( Supplementary Fig. 4g ) and Pol II, and with transcriptional activation. This differential enrichment of H3K122ac was dependent on YAP/TAZ, as robust loss in H3K122ac was observed in YAP/TAZ targets upon YAP/TAZ depletion ( Fig. 4h-k and Supplementary Fig. 4h ). Paralleling BRD4 occupancy, H3K122ac on the promoters of YAP/TAZ targets was especially sensitive to JQ1 treatment ( Fig. 4h-k and Supplementary  Fig. 4h ). Thus, we propose that YAP/TAZ promote the transcriptional activation of their target genes by favoring BRD4 overload on their promoters, therefore favoring Pol II recruitment through H3K122ac and association to Pol II.
BET inhibition opposes YAP/TAZ pro-tumorigenic functions.
To expand on the generality of the YAP/TAZ-BRD4 connection, we then asked whether YAP/TAZ transcriptional activity is especially sensitive to BET inhibitors in TNBC cell lines other than MDA-MB-231. For this, we measured the effects of YAP/TAZ depletion or JQ1 treatment on the expression level of a set of YAP/ TAZ target genes and on cell proliferation. As shown in Fig. 5a -c, TNBC cells that are YAP/TAZ addicted are also sensitive to JQ1. Interestingly, we also found one cell line, BT-20, that is not YAP/ TAZ addicted and is also resistant to BET inhibitors.
Next, we evaluated the effect of BRD4 silencing on YAP-induced cell transformation. For this, we performed a colony formation assay in soft agar with MCF10A cells, which are, per se, unable to seed colonies but acquire this capacity upon overexpression of YAP5SA. Downregulation of BRD4 (with shRNAs) reduced the number of colonies initiated by YAP-overexpressing cells ( Fig. 5d and Supplementary Fig. 5a ). In line with this, the addition of JQ1 to culture medium potently impaired initial colony formation (Fig. 5e ), as well as the growth of established colonies (Fig. 5f ), in agreement with the effects of JQ1 on the transcriptional and epigenetic effects of YAP expression.
Extending the translational significance of these findings, we assayed whether inhibition of BET proteins could blunt the growth of, if not cure, YAP/TAZ-addicted mammary tumors in vivo. Constitutive activation of the Wnt cascade in the mammary epithelium has been shown to induce TNBC-like tumors in mice 30 , a finding that parallels the high frequency of adenomatous polyposis coli (APC) epigenetic silencing in human TNBC 31 . YAP/TAZ are potently activated by aberrant Wnt signaling 9 and, consistently, MMTVcre; Apc fl/fl mice exhibited massive YAP stabilization ( Fig. 5h ). By 8 weeks of age, MMTV-cre; Apc fl/fl mice displayed massive overgrowth of the mammary epithelium, with panductal and panlobular atypical hyperplasia and fibrosis ( Fig. 5g and Supplementary Fig. 5d ), expansion of the luminal layer and large discontinuities in the basal/myoepithelial layer (Fig. 5h,j and Supplementary Fig. 5e ), collectively configuring a preneoplastic/early neoplastic scenario. Strikingly, all of these lesions did not develop in MMTV-cre; Apc fl/fl mice also bearing Yap and Taz conditional alleles ( Fig. 5g,h) , indicating that YAP/TAZ are required for epithelial overgrowth and the development of these mammary lesions. We next tested whether established, already grown neoplastic lesions in MMTV-cre; Apc fl/fl mice could be treated by administration of BET inhibitors. For this, we treated 8-week-old female mice (that is, with an overt mammary gland phenotype) with a potent BET inhibitor (BAY-1238097 (ref. 32 ), 75 mg per kg per week) for 6 weeks. Strikingly, at the end of the treatment, lesions had greatly regressed due to cell death and epithelial remodeling with few remaining signs of mammary hyperplasia or fibrosis to an extent that the main mammary ducts returned to a normal appearance (Fig. 5i,j and Supplementary Fig. 5f ). As a control, treatment of Apc fl/fl siblings (that is, lacking Cre expression) 
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was overtly well tolerated and inconsequential for mammary gland homeostasis ( Supplementary Fig. 5g,h) . Thus, BET inhibition defines a vulnerability for YAP/TAZ-driven mammary tumors, in line with the results obtained in human TNBC cell lines.
We next explored the functional dependence of YAP/TAZ on BET proteins in tissues other than the mammary gland. For this, we opted for the mouse liver, a classic model system for the study of YAP/TAZ function in vivo 33, 34 . As previously reported 35 , YAP activation in hepatocytes of adult Albumin-creERT2; R26-LSL-rtTA; tet-O-YAPS127A mice ( Supplementary Fig. 6a,b ) promotes a pre-neoplastic condition, in which differentiated hepatocytes transdifferentiate into liver progenitor cells labeled by SOX9, a YAP/ TAZ direct target in the liver (Fig. 6a) ; these cells then contribute to the generation of a 'ductular reaction' , defined by small ('oval') cells infiltrating the liver parenchyma ( Fig. 6b) . Remarkably, treatment with a BET inhibitor (BAY-1238097) abolishes the appearance of both transdifferentiating cells (captured 'in transition' by the co-expression of SOX9 and the hepatocyte-specific HNF4-α ) and ductular reactions (Fig. 6a,b and Supplementary Fig. 6c,d) siYT1  siYT2  JQ1  JQ1  OTX015  siYT1  siYT2  JQ1  OTX015  siYT1  siYT2  JQ1  OTX015  OTX015  siYT1  siYT2 SUM159 Hs578T SUM149t Note that the BAY-BET inhibitor has no effect on the histological appearance of mammary glands of Apc fl/fl (cre-negative) littermates (see Supplementary Fig. 5g ). j, Representative immunofluorescence pictures of mammary glands from MMTVcre; Apc fl/fl mice, treated with vehicle (n = 5) or the BAY-BET inhibitor (n = 5) for 6 weeks, showing that treatment with the BET inhibitor restores the normal distribution of the luminal marker K8 and the basal marker K14 in the mammary ducts. Scale bars, 25 µ m. See Supplementary Fig. 5h for normal K8 and K14 staining in Apc fl/fl (cre-negative) mice treated with the BAY-BET inhibitor.
Articles NATuRE MEDICINE Fig. 6b ). By reverse transcription qPCR (RT-qPCR) and in situ hybridization, the oval-cell marker Osteopontin (also known as Spp1) is induced in YAP transgenic livers but suppressed by concomitant treatment with a BET inhibitor ( Fig. 6c and Supplementary Fig. 6e ). Histologically, the BET inhibitor remarkably prevented the otherwise massive changes in the architecture of the liver parenchyma and reduced the appearance of proliferating Ki-67 + hepatocytes that are typically observed in vehicle-treated YAP transgenic livers ( Fig. 6b and Supplementary Fig. 6h ). Finally, liver overgrowth induced by YAP expression was inhibited by the BET inhibitor (Fig. 6d ). Next, we focused on another endoderm-derived tissue, the pancreas, testing the functional interdependency of YAP/TAZ and BRD4 in the early event of pancreatic tumor formation: acinar-to-ductal metaplasia (ADM) 36 . As recapitulated by ex vivo organoid cultures, transgenic expression of YAP in pancreatic acinar cells induces ADM, initially by turning acinar cells into ductal progenitors that only then start to proliferate 18 . Treatment with JQ1 opposes YAP-induced ADM in organoids and impairs ensuing cell proliferation (Fig. 6e,f and Supplementary Fig. 6i ), as also validated by the expression levels of the ductal marker Krt19 and Ccnd1 ( Supplementary Fig. 6j ). These data complement the data shown above for the mammary gland and expand the generality of the YAP/TAZ-BRD4 interplay to diverse gene expression programs and in distinct tissue contexts both in vitro and in vivo.
Beyond controlling tumor initiation and growth, YAP/TAZ endow cancer cells with the capacity to acquire resistance to chemotherapeutics and molecularly targeted drugs 17 . Melanoma cells bearing BRAF-activating mutations are a point in case. It has been recently shown that resistance to BRAF inhibitors (such as PLX4032 (also known as vemurafenib)) is rapidly installed in a YAP/TAZdependent manner in melanoma cells 37, 38 . In line with this, YAP overexpression in BRAF-mutant but still vemurafenib-sensitive cells is sufficient to install chemoresistance 37 . We hypothesized that JQ1 could be used to revert YAP-induced drug resistance. Indeed, the growth of YAP-overexpressing BRAF-mutant melanoma cells was strongly inhibited by the combined exposure to vemurafenib and JQ1, which was, per se, poorly active ( Fig. 6g and Supplementary  Fig. 6k ). The depletion of BET proteins in YAP-overexpressing cells or treatment with BET inhibitors impaired the expression of YAP direct target genes ( Fig. 6h and Supplementary Fig. 6l ); these genes include AXL 13 , which has been reported to be a pillar in resistance to BRAF inhibitors 39 , and the immune checkpoint PDL1 40 . Next, we wanted to verify whether JQ1 could re-sensitize cells that have spontaneously acquired resistance to vemurafenib after chronic exposure. We found that JQ1 could inhibit the activity of the TEAD luciferase reporter in vemurafenib-resistant cells ( Supplementary  Fig. 6m ), and, in viability assays, the combined treatment with JQ1 sensitized resistant cells to low doses of vemurafenib and impaired tumor cell viability to an extent that neither vemurafenib nor JQ1 could achieve when used individually ( Fig. 6i and Supplementary  Fig. 6n ). The effect of JQ1 was phenocopied by the combination of vemurafenib with two independent mixes of BRD siRNAs ( Supplementary Fig. 6o ). Collectively, these experiments indicate the requirement of BET proteins in maintaining YAP/TAZ-induced resistance to vemurafenib in BRAF-mutant melanoma cells and suggest that BET inhibitors might indeed prove useful to revert YAP/TAZ-dependent drug resistance in melanoma cells.
Our data imply that, in human tumors, a relevant fraction of the oncogenic functions of BRD4 and its associated transcriptional dependencies, may be in fact associated with the biology of YAP/ TAZ. To put this idea to the test, we analyzed a large data set of patients with breast cancer 41 containing clinical annotations and transcriptional profiling. We stratified patients according to the expression levels of BET-dependent genes, identified in MDA-MB-231 cells at the beginning of this study. Patients with a higher expression of this signature had a worse prognosis, as expected from the known oncogenic functions of BRD4 (Fig. 6j ). Remarkably, however, when we split the list of BET target genes into YAP/TAZ-dependent and -independent signatures, we found that only common YAP/TAZ/ BET target genes retained predictive value, whereas BET targets that were not YAP/TAZ-dependent did not (Fig. 6j ). This implies that the BRD4 oncogenic properties substantially rest on YAP/ TAZ transcriptional responses. Similarly, analysis of a data set of human hepatocellular carcinomas 42 with signatures of shared YAP/ TAZ/BET targets versus BET targets that were not YAP/TAZ targets (derived from analyses of YAP/TAZ-depleted or JQ1-treated HepG2 cells; see details in methods) indicated that only the shared signature was meaningful for tumor aggressiveness ( Supplementary  Fig. 6p ). Finally, in a cohort of patients with BRAF-mutant melanoma treated with vemurafenib 43 , only the expression of a signature Supplementary Fig. 6c . Scale bar, 50 µ m. Immunofluorescence was performed in n = 4 control mice, n = 4 + YAP HEP mice treated with vehicle and n = 4 + YAP HEP mice treated with the BAY-BET inhibitor. b, Representative H&E staining of liver sections from control mice + vehicle (n = 4), + YAP HEP mice + vehicle (n = 7) and + YAP HEP mice + BAY-BET inhibitor (n = 9). The lower panels are magnifications of the portal area. Scale bars, 100 μ m. Administration of the BET inhibitor to control mice had no overt consequences on liver morphology or molecular features (see Supplementary Fig. 6f,g) . c, RNA in situ hybridization on liver tissues for Osteopontin (also known as Spp1). Scale bar, 200 µ m. The experiment was performed in liver sections from two mice per experimental group with similar results. d, The BAY-BET inhibitor impairs liver overgrowth induced by YAP expression. Data are liver/body weight ratios in all examined mice (control mice + vehicle: n = 4; control mice + BAY-BET inhibitor: n = 4; + YAP HEP mice + vehicle: n = 7; and + YAP HEP mice + BAY-BET inhibitor: n = 9). The lines represent the mean of each group. ***P = 0.00098 (unpaired t-test, two tailed). e, Representative images of pancreatic acini in 3D culture, derived from the indicated mice, after 3 days of culture in the presence of doxycycline to activate YAP expression. Treatment with the BET inhibitor opposes YAP-induced ADM in organoids (see quantification in Supplementary Fig. 6i ). Scale bar, 0. 
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of shared YAP/TAZ/BET target genes in the primary tumor was associated with early disease progression ( Supplementary Fig. 6q ).
Discussion
A large body of evidence from several investigators has addressed various means by which BRD4 interacts with transcriptional regulators to nuance transcription 44 . The present discovery of a YAP/ TAZ-BRD4 axis advances on this paradigm and may suggest new therapeutic opportunities for cancer and other diseases that rely on YAP/TAZ transcriptional programs.
We have advanced on the molecular mechanisms underlying transcriptional addiction in tumor cells, identifying YAP/TAZ as relevant players in this phenomenon. The underlying molecular event is the physical and functional association between YAP/TAZ and BRD4: YAP/TAZ-bound enhancers recruit BRD4, leading to BRD4 accrual on their target promoters. We show that the YAP/ TAZ-BRD4 complex confers a transcriptional advantage to a broad number of YAP/TAZ target genes; such a transcriptional 'edge' can be targeted by BET inhibitors in different cellular and tissue contexts with tumor preventive and suppressive effects.
The present results advance on the molecular definition of enhancer elements that are responsible for transcriptional dysregulations in cancer. Major emphasis in this respect has recently been placed on super-enhancers, although the molecular identity of the key transcription factors underlying the properties of these regulatory elements remains unknown 8 . We found that super-enhancers 
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NATuRE MEDICINE largely consist of YAP/TAZ-occupied enhancers; this raises questions on the fact that numerous cancer-specific super-enhancers may simply represent the more noticeable 'tip of the iceberg' of a larger set of YAP/TAZ-bound enhancers that nonetheless display super-enhancer-like properties, as defined by strong enrichment of BRD4, a higher expression level of regulated target genes and a higher than average sensitivity to BET inhibitors. We show that the association of BRD4 to chromatin requires the dual interaction with YAP/TAZ and with acetylated histones. This is reminiscent of the previously proposed requirement of both bromodomain-dependent and -independent roles for BRD4 function 5, 25 ; such complex formation on chromatin probably involves cooperative associations akin to those postulated to stabilize distinct transcription factors bound to joined motifs at their modular cis-regulatory elements. We postulate that new therapeutics may be designed around the BET-YAP/TAZ interaction surfaces, including the YAP/TAZ WW domain, the so far poorly understood YAP/TAZ transactivation domains and the YAP/TAZ-interacting domains of BRD4, which remain here unexplored.
Drugging YAP/TAZ is clearly a very challenging yet exciting goal for cancer research 19 , given the widespread and pervasive functions of YAP/TAZ in cancer cells, contrasting their dispensability for healthy tissues; BET inhibitors may start to fulfil this unmet need. From the other perspective, BET inhibitors are promising anticancer drugs, although drug resistance and the identification of responsive patient subpopulations remain critical open issues 3 . Our results collectively indicate that the oncogenic effects of BET proteins are in close association to YAP/TAZ biology, potentially offering new perspectives on how to select patients who are more likely to receive benefit from BET inhibitors, alone or in combination with other drugs. Molecularly annotated data sets of patient cohorts treated with BET inhibitors are not yet available; however, here, we show that patients stratified according to YAP/TAZ classifiers might in fact display differential sensitivity to these drugs, as the oncogenic potential of BET proteins, as inferred from gene expression signatures, seems to be essentially contained within genes addicted to BRD4 through YAP/TAZ. YAP/TAZ are critical for inducing cell-fate plasticity in normal and tumor cells alike 17 . For example, they reprogram normal differentiated mammary cells into mammary stem cells 18 , or more differentiated tumor cells into cancer stem cells 45 . The nature of the epigenetic barriers controlling these transitions remains unknown, but it is tempting to speculate that BRD4 availability, and potentially other factors assembled by YAP/TAZ on chromatin, may link YAP/TAZ function to permissive versus restrictive chromatin states, as such guiding cell reprogramming or barring it. Thus, the YAP/TAZ-BRD4 connection may hold relevance in contexts other than cancer in which YAP/TAZ play essential roles, such as in heart repair and tissue regeneration.
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ChIP-MS. Cells were cross-linked with 1% formaldehyde (Sigma) in culture medium for 10 min at room temperature followed by 5 min treatment with 0.125 M glycine in PBS. Cells were harvested and incubated in Lysis Buffer 1 (50 mM HEPES, pH 7.5, 10 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, with protease inhibitors; 20 min at 4 °C), then in Lysis Buffer 2 (10 mM Tris-HCl, pH 8, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA, plus protease inhibitors; 10 min at room temperature). Finally, nuclei were resuspended in Lysis Buffer 3 (10 mM Tris-HCl, pH 8, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate and 0.5% N-lauroylsarcosine, plus protease inhibitors) and sonicated using a Branson Sonifier 4500D (5 × 1 min pulse, duty cycle 0.5, 30% amplitude). Immunoprecipitation was performed by incubating cleared extracts (corresponding to 2 × 10 6 cells) with 20 µ g antibody overnight at 4 °C (anti-YAP: EP1674Y, Abcam; anti-TAZ: HPA007415, Sigma; pre-immune rabbit IgGs: I5006, Sigma). Antibody-antigen complexes were recovered with Protein G Dynabeads (Invitrogen, 5 μ l Dynabeads/1 μ g antibody) for 3 h at 4 °C. The precipitates were washed twice in low-salt wash buffer (20 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1 % SDS, 0.5% Triton X-100 and 2 mM EDTA), twice in highsalt wash buffer (20 mM Tris-HCl, pH 8, 2 mM EDTA, 300 mM NaCl, 0.1% SDS and 0.5% Triton X-100) and once with 100 mM Tris-HCl. Precipitates were eluted in 7.5% SDS, 200 mM dithiothreitol and incubated at 37 °C for 30 min to revert crosslinks. Upon alkylation with iodoacetamide, proteins were purified with SP3 beads as previously described 53 , resuspended in 50 mM ammonium bicarbonate and digested with 300 ng trypsin for 16 h at 37 °C. Peptides were subjected to SP3 cleanup and they were eluted in 0.1% TFA. Samples were analyzed on an Orbitrap Fusion mass spectrometer (Thermo Fisher).
Co-IP of endogenous nuclear proteins.
Cells were rinsed twice with ice-cold HBSS and incubated with ice-cold hypotonic buffer (2 × 1 min, 20 mM HEPES, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA and 0.1% NP-40, freshly supplemented with 1 mM dithiothreitol, and protease and phosphatase inhibitor cocktails). Nuclei were then harvested by scraping in hypertonic buffer (hypotonic buffer + 500 mM NaCl, 400 µ l per 60 cm 2 ) and disrupted by sonication in a waterbath sonicator. Nuclear lysates were cleared by centrifugation and quantified by Bradford. For immunoprecipitation, extracts were diluted to 140 mM NaCl and incubated for 4 h at 4 °C with magnetic beads (Dynabeads Protein A or G, Invitrogen) preloaded with specific primary antibodies. Immunocomplexes were then washed in binding buffer four times; finally, beads were resuspended in SDS sample buffer.
Antibodies used for immunoprecipitation: anti-BRD4 (E2A7X, CST); anti-YAP1 (13584-1-AP, Proteintech); anti-WWTR1 (HPA007415, Sigma); anti-FLAG (clone M2, A8592, Sigma); and normal rabbit IgG (I5006, Sigma).
GST pull-down. GST-YAP and GST-TAZ were produced in Escherichia coli and immobilized on glutathione Sepharose 4B (GE/Sigma). Resins were blocked in 5% BSA in PBS and then incubated with full-length recombinant BRD4 (RD-21-153, Cambridge Bioscience, 500 ng per reaction) in binding buffer (20 mM HEPES KOH, 20% glycerol, 100 mM KCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% NP-40 and 1 mM dithiothreitol) overnight at 4 °C. Resins were then washed in binding buffer (4 × 5 min) and resuspended in SDS sample buffer for subsequent analysis.
Western blot. Cells were harvested in Lysis Buffer (20 mM HEPES (pH 7.8), 100 mM NaCl, 5% glycerol, 0.5% NP-40, 5 mM EDTA, 1 mM dithiothreitol and phosphatase and protease inhibitors) and lysed by sonication. About 10 mg liver were mechanically disrupted, resuspended in 500 µ l of Lysis Buffer and lysed by sonication. Extracts were quantified with the Bradford method. Samples were run in 4-12% Nupage-MOPS acrylamide gels (Thermo Fisher) and transferred onto polyvinylidene difluoride (PVDF) membranes by wet electrophoretic transfer. Blots were blocked with 0.5% non-fat dry milk and incubated overnight at 4 °C with primary antibodies. Secondary antibodies were incubated for 1 h at room Luciferase reporter assays. Luciferase assays were performed in M229 and M229-R5 cells with the TEAD reporter 8xGTIIC-Lux. The luciferase reporter (25 ng per cm 2 ) was transfected together with CMV-β -galactosidase (25 ng per cm 2 ) to normalize for transfection efficiency with the CPRG (Roche) colorimetric assay. DNA content in all samples was kept uniform by adding a pBluescript plasmid up to 250 ng per cm 2 . Cells were plated at 20% confluence (day 0) and the following day (day 1) transfected with DNA. After 6 h, cells were treated with different doses of JQ1 (1 nM, 10 nM, 0.1 µ M and 1 µ M). Cells were harvested after 24 h of treatment (day 2). Firefly luciferase activity was measured with an Infinite F200PRO plate reader (Tecan), using luciferin (Sigma) as a substrate. Data are presented as firefly/β -galactosidase activity. Each sample was transfected in duplicate and each experiment was repeated at least three times independently with similar results. Viability assays. Cells were seeded in 96-well plates (4,000 cells per well) 1 day before treatment with drugs or transfection with siRNAs. Cells were fixed after 72 h with a crystal violet solution (0.05% w/v crystal violet, 1% formaldehyde and 1% methanol in PBS) for 20 min at room temperature; stained cells were washed with water until a clear background was visible and air dried. Crystal violet was extracted with 1% SDS (w/v in double-distilled water, 100 μ l per well) and absorbance at λ = 595 nm was measured with an Infinite F200PRO plate reader (Tecan). Eight wells were analyzed for each experimental condition; data are presented as mean + s.d. Data are presented as the % viability compared to control cells (treated with DMSO or transfected with control siRNA (siCO)): absorbance at the beginning of treatment was set as 0% and absorbance at the end of experiment was set as 100%. Each experiment was performed at least twice, with similar results.
Colony formation assay in soft agar. MCF10A cells (10 4 ) and MDA-MB-231 cells (3 × 10 4 ) were resuspended in complete growth medium with 0.35% agarose (Invitrogen) and were layered onto 0.5% agar beds in six-well plates. Complete medium was added on top of cells and was replaced with fresh medium twice a week for 3 weeks. Complete medium contained 1 µ g ml -1 doxycycline to activate the expression of shRNAs, where necessary. The indicated doses of JQ1 were added to the culture, starting 24 h after seeding (unless differently specified). Assays were conducted in triplicate. For MCF10A cells, all colonies in a well were counted. For MDA-MB-231 cells, colonies were counted in six fields of each samples and the average number of colonies per field was calculated for each sample. Experiments contained three independent samples for each condition and were performed three times, with similar results.
Isolation and culture of pancreatic acini. Primary pancreatic acini were isolated as described in Panciera et al. 18 from rtTAM2; colYAP mice or from rtTAM2 littermates as control (both male and females, 6-8-weeks old). Acini were seeded in neutralized rat tail collagen type I (Cultrex)/acinar culture medium (1:1) 54 and overlaid with acinar culture medium (Waymouth's medium (Life Technologies) supplemented with 0.1% FBS (Life Technologies), 0.1% BSA, 0.2 mg ml -1 soybean trypsin inhibitor, 1× insulin-transferrin-selenium-ethanolamine (Life Technologies), 50 μ g ml -1 BPE (Life Technologies), 1 μ g ml -1 dexamethasone (Sigma) and antibiotics) supplemented with 0.5 μ g ml -1 doxycycline and DMSO or 10 μ M JQ1, as indicated. ADM events were counted 2-4 days after seeding. For EdU incorporation, 20 μ M EdU was added to culture medium for 90 min, then collagen cushions containing acini or ducts were extensively washed in PBS and fixed in 4% PFA for 20 min at room temperature. EdU staining was performed with Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific), according to the manufacturer's instructions. Total RNA was extracted with TRIzol reagent (Invitrogen).
Mice.
Animal experiments were performed adhering to our institutional guidelines as approved by the OPBA (University of Padua) and the Italian Ministry of Health. All experimental mice used in this study were mixed strains and more than 6-weeks old; for mammary gland experiments, we used exclusively female mice. Transgenic lines used in the experiments were kindly provided by: D. Pan 55 (Yap1 fl/fl ); A. R. Clarke 56 (Apc fl/fl ); F. Camargo 33 (tetO-YAPS127A); P. Chambon 57 (Albumin-creERT2). Taz fl/fl and double Yap fl/fl ; Taz fl/fl conditional knockout mice were as described in ref. 9 . MMTV-cre 58 (stock 003553) and R26-LSL-rtTA 59 (stock 005670) were purchased from The Jackson Laboratory. Yap, Taz and Apc conditional knockouts were intercrossed with MMTV-cre mice to obtain the different genotypes. Mice carrying Albumin-creERT2, R26-LSL-rtTA and tetO-YAPS127A alleles were intercrossed to obtain Albumin-creERT2; R26-LSL-rtTA/ + ; tetO-YAPS127A mice. Albumin-creERT2; R26-LSL-rtTA/ + littermates were used as control. Animals were genotyped with standard procedures and with the recommended set of primers.
Control (Apc fl/fl , n = 5) or MMTV-cre; Apc fl/fl (n = 5) mice were administered the BAY-BET inhibitor (BAY-1238097) by intraperitoneal injection for 6 weeks, starting at 8 weeks of age (15 mg per kg, 5 injections per week). Control mice were injected with vehicle (0.9% NaCl, pH 4). Harvesting, processing and stainings on mammary glands were performed as in ref. 18 .
For the induction of the recombination in the liver, control (Albumin-creERT2; R26-LSL-rtTA/ + ) mice and Albumin-creERT2; R26-LSL-rtTA/ + ; tetO-YAPS127A mice received 1 intraperitoneal injection per day of 3 mg tamoxifen (Sigma) dissolved in corn oil (Sigma) during 2 consecutive days. After 2 weeks, mice were administered doxycycline in drinking water for 10 days, during which they also received the BAY-BET inhibitor (15 mg per kg, 5 injections per week) or vehicle by intraperitoneal injections, as indicated in the corresponding Figures.
For validation of the Albumin-CreERT2 driver ( Supplementary Fig. 6a ), Albumin-creERT2; R26-LSL-YFP/ + mice were injected with 3 mg tamoxifen (Sigma) per day dissolved in corn oil (Sigma) during 5 consecutive days and were killed after 2 weeks.
Immunostainings and immunofluorescences of liver tissue.
Immunohistochemical staining was performed on formalin-fixed, paraffinembedded tissue sections as described in ref. 45 . Primary anti-Ki-67 polyclonal antibody (clone SP6; M3062) was from Spring Bioscience.
Immunofluorescences on PFA-fixed, paraffin-embedded tissue slices was performed as in ref. 45 . Primary antibodies were anti-cytokeratin (wide-spectrum screening, ZO622, Dako), anti-HNF4-α (sc-6556, Santa Cruz Biotechnology), anti-SOX9 (AB5535, Millipore) and anti-GFP (ab13970, Abcam). Samples were counterstained with ProLong-DAPI (Molecular Probes, Life Technologies) to label cell nuclei. Confocal images were obtained with a Leica TCS SP5 equipped with a CCD camera. Bright-field images were obtained with a Nanozoomer Scanner 2.0RS (Hamamatsu). 60 (version 2.0.5) to build version hg19 of the human genome. Counts for UCSC annotated genes were calculated from the aligned reads using HTSeq 61 (version 0.6.0). Normalization and differential analysis were carried out using edgeR package 62 and R (version 3.0.0). Raw counts were normalized to obtain counts per million mapped reads (CPM) and reads per kilobase per million mapped reads (RPKM). Only genes with a RPKM greater than one in at least two samples were retained for differential analysis. Genes were considered differentially expressed with a Benjamini-Hochberg false discovery rate (FDR) ≤ 1% and a fold change ≤ 0.75. The 10th percentile, first quartile, median, third quartile and 90th percentile are plotted in box-and-whiskers graphs. Fold changes were calculated as the ratio of RPKM. GO analysis. GO analyses were performed on all the genes expressed in MDA-MB-231 cells (RNA-seq RPKM ≥ 1) using Enrichr (http://amp.pharm.mssm. edu/Enrichr/) 63, 64 . Genes annotated with GO terms related to cell cycle (for example, GO:0000278: mitotic cell cycle and GO:0008283: cell proliferation), DNA replication and repair (for example, GO:0006260: DNA replication and GO:0006281: DNA repair), mitosis (for example, GO:0000279: M phase and GO:0007067: mitosis), cytokinesis (for example, GO:0000281: mitotic cytokinesis and GO:0051301: cell division), microtubule cytoskeleton (for example, GO:0007020: microtubule nucleation and GO:0007051: spindle organization) and telomere maintenance (for example, GO:0000723: telomere maintenance) were included in a single category named 'cell proliferation' .
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ChIP-seq and ChIP-qPCR. ChIP was performed as previously described 13 . Briefly, cells were crosslinked with 1% formaldehyde (Sigma) in culture medium for 10 min at room temperature, and chromatin from lysed nuclei was sheared to 200-600-bp fragments using a Branson Sonifier 4500D.
For ChIP-seq, ~200 μ g chromatin were incubated with 10 μ g antibody overnight at 4 °C (anti-BRD4: A301-985A, Bethyl-Lab; anti-Pol II: ab817, Abcam; normal rabbit IgG: Sigma; normal mouse IgG: Santa Cruz). For ChIP-seq of H3K122ac, ~50 μ g chromatin were incubated with 10 μ g anti-histone H3 (acetyl K122) (ab33309, Abcam). Antibody-antigen complexes were recovered with Protein A Dynabeads (Invitrogen, 5 μ l Dynabeads/1 μ g antibody) for 2 h at 4 °C (1 h for anti-H3K122ac). The precipitates were washed and eluted in 50 mM Tris-HCl, pH 8, 1% SDS and 1 mM EDTA for 20 min at 65 °C. Chromatin was decrosslinked, treated with RNaseA and proteinase K and DNA was purified by the QIAquick PCR Purification Kit (28106, Qiagen). The enrichment of target sequences was checked by qPCR, then libraries were generated with the Ovation Ultra Low Library Prep Kit (NuGEN) according to the manufacturer's instructions. Sequencing was performed on an Illumina HiSeq 2500 platform.
For ChIP-qPCR, 100 μ g sheared chromatin and 3-5 μ g antibody were used. For ChIPs of YAP, anti-YAP1 (ab52771) from Abcam was used. For ChIPs of H3K122ac, at least 10 μ g chromatin were incubated with 2 μ g antibody. RT-qPCR was carried out with QuantStudio 5 thermal cycler (Thermo Fisher); each sample was analyzed in triplicate and was presented as the mean + s.d. The amount of immunoprecipitated DNA in each sample was determined as the fraction of the input [amplification efficiency × (Ct INPUT -Ct ChIP)], and normalized to the IgG control.
Duplicate experiments were performed at least twice with similar results. Primers used are: ANKRD1: AAAAAGGGCAGTGATGTGGTG, GAAGAGGGAGGGGAGGACAA;
CCNA2 enhancer: ACAGAAGGGGAGCGACTGG, CCCACCGTTTTCACTTTTTC;
CDC6 enhancer: GCTGGGCATCACAGTCTTGG, GGCATGGCTGGGTGACTC;
CDC6 TSS: CAAGGCGAAAGGCTCTGTGA, CAAGCCCCTGAACAAACTGC;
CDCA5 enhancer: AGTGCTGCTCCCCCACACTA, CCTGCAAGGAAAGAGCTGGA;
CDCA5 TSS: GCGTTCGCCTCCCAGACATA, TTCCGCTTCCTTTCCCGCAG;
CYR61: CACACACAAAGGTGCAATGGAG, CCGGAGCCCGCCTTTTATAC;
ETS1 enhancer: CCCTTGTCCCAACACACACA, AAAACTGTCTCCACCTCCTAATGC;
E2F3 TSS: GCGTAAACCGTATCCCTTCA, CAAAAATAATCGGGGCTCTGG;
FOSL1 TSS: TACACGGCTGCTGGGTTC, GGTGGAGCCTGGAGGTGAC; GAPDH TSS: TCGCTCTCTGCTCCTCCTGT, GTTTCTCTCCGCCCGTCTTC;
GINS1 enhancer: CCCCAAAAGTGTCCATGACC, CAGGATCACCCCCATCTCAA;
GINS1 TSS: GCCGAGAGCCCAGATACCAT, CGTTGAAGGCAGGCAGTAG; HBB: GCTTCTGACACAACTGTGTTCACTAGC, CACCAACTTCATCCACGTTCACC;
KIF23 TSS: TTGGCCCGTTTGAAATGCGC, ACGTTAGGACCGGCAGCAAG;
MCM3 enhancer: AGTTGGGATAGGCGGAGACC, GCAGGTGGGGCTTGTTTAGG;
MCM3 TSS: TCCCGCCACCAAAGGTTAC, AGCGGAAAACCCGAAGAAGA;
PLAU enhancer: GCTGGCTTCACCCTTCACAC, ATGGGGCAGACGGACTCTTC;
PLAU TSS: CCTCAGTCCAGACGCTGTTG, CTCCCTCCCCTGTCTTGCAG; RRM2 enhancer: AGGGCTGTTGCTCACCTCTTG, GCATTCTTCCTGGCTCTTTGTG;
RRM2 TSS: TTAAAGGCTGCTGGAGTGAGG, CGGAGGGAGAGCATAGTGGA;
TMEM200B TSS: AAAGGGAGGGCGAGGGAGAA, CAGCGCGGTGGTTCTTTAGGA;
TOP2A enhancer: CCCCACCCAGACAGGAAA, TGAGGCAGGGCAGTTTAGAA;
TUBB enhancer: ACTGGCTTCGGCTGTGTCTT, AATAAAGGATGTGGGGAGCA;
TUBB TSS: TTCTTGGCAGGCACATTTTG, GACCGTTTCCGCATCTCTCT.
Analysis of ChIP-seq data. Raw reads were aligned using Bowtie 65 (version 0.12.7) to build version hg19 of the human genome, retaining only uniquely mapped reads. Redundant reads were removed using SAMtools. The lists of monomethylation of H3K4 (H3K4me1)-, trimethylation of H3K4 (H3K4me3)-, H3K27ac-, YAP-and TAZ-enriched regions (peaks) in MDA-MB-231 cells were already described in ref. 13 .
The overlap of peaks from different ChIP-seq experiments was determined using the BEDTools2 suite 66 .
Definition of promoters and enhancers. To define promoter regions in the genome of MDA-MB-231 cells, we first defined a list of 2-kb-wide regions centered on each TSS mapped in the build version hg19 of the human genome (downloaded from the UCSC genome browser 67 ). We then obtained a list of promoter regions by including only the TSSs overlapping with H3K4me3-enriched regions.
Active enhancers were defined as non-promoter regions displaying enrichment for H3K4me1 and H3K27ac. For this, we first defined a list of enhancers based on H3K4me1 peaks, purged of those overlapping with promoter regions. The width of each enhancer was set to the same as the corresponding H3K4me1 peak. From this list, we generated a list of active enhancers, by including only the enhancer elements overlapping with peaks for H3K27ac.
Annotation of active enhancers to target genes. Active enhancers were annotated using the chromatin interactions reported in Supplementary Data 2 of Jin et al. 68 , derived from a high-resolution Hi-C experiment; the data sheets report the genomic locations of all target peaks interacting with more than 10,000 anchors located at gene promoters. Active enhancers overlapping with these target peaks were assigned to the corresponding interacting promoter region. 
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